

# David Goldstein

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/546740/david-goldstein-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

264  
papers

12,988  
citations

50  
h-index

110  
g-index

285  
ext. papers

15,384  
ext. citations

5.2  
avg, IF

5.97  
L-index

#	Paper	IF	Citations
264	Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 1691-703	59.2	3788
263	Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 315, 1844-53	27.4	538
262	Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. <i>Pancreas</i> , <b>2004</b> , 29, 179-87	2.6	440
261	Chemotherapy-induced peripheral neurotoxicity: a critical analysis. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2013</b> , 63, 419-37	220.7	410
260	nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	368
259	Pancreatic stellate cells: partners in crime with pancreatic cancer cells. <i>Cancer Research</i> , <b>2008</b> , 68, 2085-93	10.1	351
258	Role of pancreatic stellate cells in pancreatic cancer metastasis. <i>American Journal of Pathology</i> , <b>2010</b> , 177, 2585-96	5.8	257
257	Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 504-12	2.2	254
256	Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 5705-14	2.2	239
255	Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106, djt347	9.7	191
254	Oxaliplatin-induced neurotoxicity and the development of neuropathy. <i>Muscle and Nerve</i> , <b>2005</b> , 32, 51-60	9.4	170
253	Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. <i>Brain</i> , <b>2009</b> , 132, 2712-23	11.2	155
252	STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review). <i>International Journal of Oncology</i> , <b>2012</b> , 41, 1181-91	4.4	148
251	Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. <i>Oncologist</i> , <b>2011</b> , 16, 708-16	5.7	148
250	What is hemoglobin A1c? An analysis of glycated hemoglobins by electrospray ionization mass spectrometry. <i>Clinical Chemistry</i> , <b>1998</b> , 44, 1951-1958	5.5	144
249	Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2728-35	2.2	138
248	Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. <i>Gut</i> , <b>2019</b> , 68, 663-671	19.2	138

247	Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 4089-95	2.2	128
246	The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , <b>2019</b> , 269, 520-529	7.8	127
245	Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. <i>BMC Cancer</i> , <b>2015</b> , 15, 564	4.8	125
244	Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1243-9	2.2	125
243	Meta-analysis of radical resection rates and margin assessment in pancreatic cancer. <i>British Journal of Surgery</i> , <b>2015</b> , 102, 1459-72	5.3	124
242	Characterisation of Immune and Neuroinflammatory Changes Associated with Chemotherapy-Induced Peripheral Neuropathy. <i>PLoS ONE</i> , <b>2017</b> , 12, e0170814	3.7	121
241	Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4275-83	2.2	102
240	Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. <i>Oncologist</i> , <b>2015</b> , 20, 143-50	5.7	99
239	Cancer-related fatigue in women with breast cancer: outcomes of a 5-year prospective cohort study. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1805-12	2.2	99
238	Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 3170-9	12.9	95
237	Barriers and facilitators of exercise experienced by cancer survivors: a mixed methods systematic review. <i>Supportive Care in Cancer</i> , <b>2018</b> , 26, 685-700	3.9	95
236	Role of pancreatic stellate cells in chemoresistance in pancreatic cancer. <i>Frontiers in Physiology</i> , <b>2014</b> , 5, 141	4.6	90
235	Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy. <i>European Journal of Cancer</i> , <b>2017</b> , 73, 22-29	7.5	85
234	Clinical and molecular characterization of HER2 amplified-pancreatic cancer. <i>Genome Medicine</i> , <b>2013</b> , 5, 78	14.4	82
233	APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4000-4000	2.2	78
232	Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. <i>British Journal of Cancer</i> , <b>2015</b> , 113, 1571-80	8.7	76
231	Key role of pancreatic stellate cells in pancreatic cancer. <i>Cancer Letters</i> , <b>2016</b> , 381, 194-200	9.9	76
230	Immigrants' perceptions of the quality of their cancer care: an Australian comparative study, identifying potentially modifiable factors. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1643-9	10.3	76

229	If I am in the mood, I enjoy it: an exploration of cancer-related fatigue and sexual functioning in women with breast cancer. <i>Oncologist</i> , <b>2011</b> , 16, 1333-44	5.7	75
228	Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. <i>British Journal of Cancer</i> , <b>2009</b> , 101, 998-1004	8.7	73
227	Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. <i>Annals of Oncology</i> , <b>2019</b> , 30, 1472-1478	10.3	71
226	Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. <i>Annals of Oncology</i> , <b>2016</b> , 27, 134-40	10.3	69
225	Fatigue states after cancer treatment occur both in association with, and independent of, mood disorder: a longitudinal study. <i>BMC Cancer</i> , <b>2006</b> , 6, 240	4.8	69
224	Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer. <i>British Journal of Cancer</i> , <b>2016</b> , 114, 269-80	8.7	66
223	CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. <i>Annals of Oncology</i> , <b>2016</b> , 27, 654-60	10.3	62
222	Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial. <i>Haematologica</i> , <b>2015</b> , 100, 955-63	6.6	60
221	The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: antiangiogenic implications in pancreatic cancer. <i>Carcinogenesis</i> , <b>2014</b> , 35, 1891-900	4.6	60
220	Pancreatic cancer: The microenvironment needs attention too!. <i>Pancreatology</i> , <b>2015</b> , 15, S32-8	3.8	59
219	Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification. <i>Journal of Infectious Diseases</i> , <b>1998</b> , 178, 858-61	7	57
218	Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, LBA4003-LBA4003	2.2	55
217	A Rationally Optimized Nanoparticle System for the Delivery of RNA Interference Therapeutics into Pancreatic Tumors in Vivo. <i>Biomacromolecules</i> , <b>2016</b> , 17, 2337-51	6.9	54
216	Fatigue and psychological distress--exploring the relationship in women treated for breast cancer. <i>European Journal of Cancer</i> , <b>2004</b> , 40, 1689-95	7.5	52
215	Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. <i>British Journal of Cancer</i> , <b>2016</b> , 115, 188-94	8.7	52
214	Communicating in a multicultural society. II: Greek community attitudes towards cancer in Australia. <i>Internal Medicine Journal</i> , <b>2002</b> , 32, 289-96	1.6	50
213	Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP). <i>British Journal of Cancer</i> , <b>2016</b> , 115, 281-9	8.7	48
212	βII-tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 2235-49	3.3	48

211	A serious complication of selected internal radiation therapy: case report and literature review. <i>Oncologist</i> , <b>2010</b> , 15, 830-5	5.7	47
210	Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. <i>Supportive Care in Cancer</i> , <b>2017</b> , 25, 3485-3493	3.9	45
209	Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer. <i>Frontiers in Physiology</i> , <b>2014</b> , 5, 2	4.6	45
208	Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. <i>BMC Cancer</i> , <b>2016</b> , 16, 22	4.8	43
207	A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients. <i>Annals of Oncology</i> , <b>2012</b> , 23, 1335-1340	10.3	41
206	Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 479-80	59.2	40
205	Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial. <i>Journal of Gastrointestinal Oncology</i> , <b>2016</b> , 7, 469-78	2.8	38
204	Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathy. <i>Supportive Care in Cancer</i> , <b>2019</b> , 27, 3849-3857	3.9	38
203	Targeting the HGF/c-MET pathway: stromal remodelling in pancreatic cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 76722-76739	3.5	37
202	Anxiety, depression and quality of life in people with pancreatic cancer and their carers. <i>Pancreatology</i> , <b>2017</b> , 17, 321-327	3.8	35
201	Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations. <i>Genetics in Medicine</i> , <b>2015</b> , 17, 391-5	8.1	35
200	Migrant health in cancer: outcome disparities and the determinant role of migrant-specific variables. <i>Oncologist</i> , <b>2015</b> , 20, 523-31	5.7	34
199	Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, LBA148-LBA148	2.2	34
198	The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04). <i>European Journal of Cancer</i> , <b>2016</b> , 55, 15-26	7.5	33
197	Human papillomavirus (HPV) genotypes in an Australian sample of anal cancers. <i>International Journal of Cancer</i> , <b>2014</b> , 135, 996-1001	7.5	33
196	Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer. <i>Clinical Neurophysiology</i> , <b>2017</b> , 128, 1166-1175	4.3	32
195	Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence. <i>OncoTargets and Therapy</i> , <b>2016</b> , 9, 5461-73	4.4	32
194	Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. <i>Lancet Oncology</i> , <b>2018</b> , 19, e151-e160	21.7	31

193	The Potential of panHER Inhibition in Cancer. <i>Frontiers in Oncology</i> , <b>2015</b> , 5, 2	5.3	30
192	Randomized Evaluation of Cognitive-Behavioral Therapy and Graded Exercise Therapy for Post-Cancer Fatigue. <i>Journal of Pain and Symptom Management</i> , <b>2017</b> , 54, 74-84	4.8	29
191	Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas. <i>Annals of Oncology</i> , <b>2016</b> , 27, 648-53	10.3	29
190	Describing Patterns of Care in Pancreatic Cancer: A Population-Based Study. <i>Pancreas</i> , <b>2015</b> , 44, 1259-65	2.6	29
189	Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer. <i>British Journal of Cancer</i> , <b>2007</b> , 97, 464-71	8.7	29
188	Targeting the undruggable in pancreatic cancer using nano-based gene silencing drugs. <i>Biomaterials</i> , <b>2020</b> , 240, 119742	15.6	29
187	Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT). <i>European Journal of Cancer</i> , <b>2016</b> , 52, 85-91	7.5	29
186	Modern management of pancreatic carcinoma. <i>Internal Medicine Journal</i> , <b>2004</b> , 34, 475-81	1.6	28
185	A tsunami of unmet needs: pancreatic and ampullary cancer patients' supportive care needs and use of community and allied health services. <i>Psycho-Oncology</i> , <b>2016</b> , 25, 150-7	3.9	28
184	Communication challenges experienced by migrants with cancer: A comparison of migrant and English-speaking Australian-born cancer patients. <i>Health Expectations</i> , <b>2017</b> , 20, 886-895	3.7	27
183	Prognostic factors predictive of response and survival to a modified FOLFOX regimen: importance of an increased neutrophil count. <i>Clinical Colorectal Cancer</i> , <b>2006</b> , 6, 297-304	3.8	27
182	Australian Leukaemia Study Group myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma. <i>British Journal of Haematology</i> , <b>1997</b> , 97, 38-45	4.5	26
181	Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study. <i>Oncology</i> , <b>2005</b> , 69, 326-32	3.6	24
180	Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 947-954	8.7	23
179	Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 852-60	7.5	21
178	Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?. <i>European Journal of Cancer</i> , <b>2016</b> , 53, 96-104	7.5	21
177	Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients. <i>British Journal of Cancer</i> , <b>2005</b> , 92, 832-7	8.7	21
176	Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT). <i>Practical Radiation Oncology</i> , <b>2020</b> , 10, e136-e146	2.8	21

175	Information needs of the Chinese community affected by cancer: A systematic review. <i>Psycho-Oncology</i> , <b>2017</b> , 26, 1433-1443	3.9	20
174	New molecular and immunotherapeutic approaches in biliary cancer. <i>ESMO Open</i> , <b>2017</b> , 2, e000152	6	20
173	Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study. <i>Pancreas</i> , <b>2017</b> , 46, 203-208	2.6	20
172	Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade. <i>Supportive Care in Cancer</i> , <b>2019</b> , 27, 4771-4777	3.9	19
171	Targeting the PI3K/PTEN/AKT/mTOR Pathway in Treatment of Sarcoma Cell Lines. <i>Anticancer Research</i> , <b>2016</b> , 36, 5765-5771	2.3	19
170	Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis. <i>British Journal of Cancer</i> , <b>2020</b> , 122, 1486-1495	8.7	18
169	Overcoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcoma. <i>Oncotarget</i> , <b>2016</b> , 7, 21496-509	3.3	18
168	Determinants of Outcomes Following Resection for Pancreatic Cancer-a Population-Based Study. <i>Journal of Gastrointestinal Surgery</i> , <b>2016</b> , 20, 1471-81	3.3	18
167	Communicating with patients from minority backgrounds: Individual challenges experienced by oncology health professionals. <i>European Journal of Oncology Nursing</i> , <b>2017</b> , 26, 83-90	2.8	17
166	Oxaliplatin induces muscle loss and muscle-specific molecular changes in Mice. <i>Muscle and Nerve</i> , <b>2018</b> , 57, 650-658	3.4	17
165	Characterization of fatigue states in medicine and psychiatry by structured interview. <i>Psychosomatic Medicine</i> , <b>2014</b> , 76, 379-88	3.7	17
164	Phase II study of vinflunine in patients with metastatic renal cell carcinoma. <i>Investigational New Drugs</i> , <b>2006</b> , 24, 429-34	4.3	17
163	CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine. <i>Future Oncology</i> , <b>2019</b> , 15, 1295-1302	3.6	17
162	"I might not have cancer if you didn't mention it": a qualitative study on information needed by culturally diverse cancer survivors. <i>Supportive Care in Cancer</i> , <b>2016</b> , 24, 409-418	3.9	16
161	Factors associated with quality of care for patients with pancreatic cancer in Australia. <i>Medical Journal of Australia</i> , <b>2016</b> , 205, 459-465	4	16
160	Risk factors for current and future unmet supportive care needs of people with pancreatic cancer. A longitudinal study. <i>Supportive Care in Cancer</i> , <b>2016</b> , 24, 3589-99	3.9	16
159	Circulating pancreatic stellate (stromal) cells in pancreatic cancer-a fertile area for novel research. <i>Carcinogenesis</i> , <b>2017</b> , 38, 588-591	4.6	15
158	Optimizing Clinical Screening for Chemotherapy-Induced Peripheral Neuropathy. <i>Journal of Pain and Symptom Management</i> , <b>2019</b> , 58, 1023-1032	4.8	15

157	Post-cancer fatigue is not associated with immune activation or altered cytokine production. <i>Annals of Oncology</i> , <b>2012</b> , 23, 2890-2895	10.3	15
156	Impact of chemoradiotherapy (CRT) on local control and time without treatment in patients with locally advanced pancreatic cancer (LAPC) included in the international phase III LAP 07 study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4001-4001	2.2	15
155	Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition. <i>Cancer Research</i> , <b>2021</b> , 81, 3461-3479	10.1	15
154	Impact of STAT3 inhibition on survival of osteosarcoma cell lines. <i>Anticancer Research</i> , <b>2014</b> , 34, 6537-452.3	5.3	15
153	Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib. <i>JAMA Surgery</i> , <b>2020</b> , 155, e200397	5.4	14
152	TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2016</b> , 78, 361-7	3.5	14
151	Oncology service initiatives and research in regional Australia. <i>Australian Journal of Rural Health</i> , <b>2015</b> , 23, 40-8	1.3	14
150	Exploiting base excision repair to improve therapeutic approaches for pancreatic cancer. <i>Frontiers in Nutrition</i> , <b>2015</b> , 2, 10	6.2	14
149	Rituximab to treat gemcitabine-induced hemolytic-uremic syndrome (HUS) in pancreatic adenocarcinoma: a case series and literature review. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2017</b> , 79, 1-7	3.5	13
148	The GOFURTO Study: AGITG phase II study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer. <i>British Journal of Cancer</i> , <b>2012</b> , 106, 61-9	8.7	13
147	Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, LBA4003-LBA4003	2.2	13
146	Refining the care of patients with pancreatic cancer: the AGITG Pancreatic Cancer Workshop consensus. <i>Medical Journal of Australia</i> , <b>2016</b> , 204, 419-22	4	13
145	Delineating the Role of $\beta$ -Tubulins in Pancreatic Cancer: $\beta$ -Tubulin Inhibition Sensitizes Pancreatic Cancer Cells to Vinca Alkaloids. <i>Neoplasia</i> , <b>2016</b> , 18, 753-764	6.4	13
144	Monitoring quality of care for patients with pancreatic cancer: a modified Delphi consensus. <i>Hpb</i> , <b>2019</b> , 21, 444-455	3.8	13
143	Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3. <i>Pancreatology</i> , <b>2016</b> , 16, 1106-1112	3.8	12
142	Patient perspectives on molecular tumor profiling: "Why wouldn't you?". <i>BMC Cancer</i> , <b>2019</b> , 19, 753	4.8	12
141	Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials. <i>BMC Cancer</i> , <b>2017</b> , 17, 262	4.8	12
140	Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 178-178	2.2	12



139	Balance Deficits and Functional Disability in Cancer Survivors Exposed to Neurotoxic Cancer Treatments. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2019</b> , 17, 949-955	7.3	12
138	The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study. <i>Oncologist</i> , <b>2016</b> , 21, 618-25	5.7	12
137	Dorsal root ganglion explants derived from chemotherapy-treated mice have reduced neurite outgrowth in culture. <i>Neuroscience Letters</i> , <b>2019</b> , 694, 14-19	3.3	12
136	Quantification of Small Fiber Neuropathy in Chemotherapy-Treated Patients. <i>Journal of Pain</i> , <b>2020</b> , 21, 44-58	5.2	12
135	Ex vivo culture of intact human patient derived pancreatic tumour tissue. <i>Scientific Reports</i> , <b>2021</b> , 11, 1944	4.9	12
134	Chemotherapy in patients with unresected pancreatic cancer in Australia: A population-based study of uptake and survival. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2018</b> , 14, 326-336	1.9	11
133	It's all good on the surface: care coordination experiences of migrant cancer patients in Australia. <i>Supportive Care in Cancer</i> , <b>2016</b> , 24, 2403-10	3.9	11
132	Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4005-4005	2.2	11
131	Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2036695	10.4	11
130	Mobility in survivors with chemotherapy-induced peripheral neuropathy and utility of the 6-min walk test. <i>Journal of Cancer Survivorship</i> , <b>2019</b> , 13, 495-502	5.1	10
129	Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2015</b> , 75, 993-1004	3.5	10
128	The PiGeOn project: protocol of a longitudinal study examining psychosocial and ethical issues and outcomes in germline genomic sequencing for cancer. <i>BMC Cancer</i> , <b>2018</b> , 18, 454	4.8	10
127	ESPAC-3(v2): A multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, LBA4505-LBA4505	2.2	10
126	Determinants of survival and attempted resection in patients with non-metastatic pancreatic cancer: An Australian population-based study. <i>Pancreatology</i> , <b>2016</b> , 16, 873-81	3.8	10
125	Chemotherapy-Induced Peripheral Neurotoxicity in Cancer Survivors: Predictors of Long-Term Patient Outcomes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2021</b> , 19, 821-828	7.3	10
124	EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma. <i>Annals of Oncology</i> , <b>2015</b> , 26, 1118-1123	10.3	9
123	Significance of Phosphorylated Epidermal Growth Factor Receptor and Its Signal Transducers in Human Soft Tissue Sarcoma. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	9
122	Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2011</b> , 67, 519-25	3.5	9

121	The potential of circulating tumor DNA (ctDNA) to guide adjuvant chemotherapy decision making in locally advanced rectal cancer (LARC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3521-3521	2.2	9
120	MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity. <i>Oncotarget</i> , <b>2017</b> , 8, 9216-9229	3.3	9
119	Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1109-1117	13.4	9
118	Evaluation of an online communication skills training programme for oncology nurses working with patients from minority backgrounds. <i>Supportive Care in Cancer</i> , <b>2019</b> , 27, 1951-1960	3.9	9
117	The impact of anticancer drugs on the ocular surface. <i>Ocular Surface</i> , <b>2020</b> , 18, 403-417	6.5	8
116	The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis. <i>PLoS ONE</i> , <b>2017</b> , 12, e0172307	3.7	8
115	A double blind, placebo controlled, phase II randomised cross-over trial investigating the use of duloxetine for the treatment of chemotherapy-induced peripheral neuropathy. <i>Contemporary Clinical Trials</i> , <b>2018</b> , 70, 135-138	2.3	8
114	INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG) Final overall and subgroup results.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4003-4003	2.2	8
113	APACT: Phase III randomized trial of adjuvant treatment with nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with resected pancreatic cancer (PC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS473-TPS473	2.2	8
112	Integrate II: A randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC) An international study organized by the Australasian Gastrointestinal Trials Group (AGITG).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS4136-TPS4136	2.2	8
111	Targeting HGF/c-MET Axis in Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	8
110	The PiGeOn project: protocol for a longitudinal study examining psychosocial, behavioural and ethical issues and outcomes in cancer tumour genomic profiling. <i>BMC Cancer</i> , <b>2018</b> , 18, 389	4.8	7
109	Association between pancreatic cancer patients' perception of their care coordination and patient-reported and survival outcomes. <i>Palliative and Supportive Care</i> , <b>2018</b> , 16, 534-543	2.5	7
108	Using a Delphi process to determine optimal care for patients with pancreatic cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2016</b> , 12, 105-114	1.9	7
107	Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review. <i>Journal of Cancer Survivorship</i> , <b>2021</b> , 1	5.1	7
106	Challenges and perceived unmet needs of Chinese migrants affected by cancer: Focus group findings. <i>Journal of Psychosocial Oncology</i> , <b>2019</b> , 37, 383-397	2.8	6
105	Acute changes in nerve excitability following oxaliplatin treatment in mice. <i>Journal of Neurophysiology</i> , <b>2020</b> , 124, 232-244	3.2	6
104	The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer. <i>Annals of Surgical Oncology</i> , <b>2020</b> , 27, 2506-2515	3.1	6

103	INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC) A study by the Australasian Gastrointestinal Trials Group (AGITG), first results.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 9-9	2.2	6
102	Potential role of circulating tumor DNA (ctDNA) in the early diagnosis and post-operative management of localised pancreatic cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4101-4101	2.2	6
101	Multimodality treatment of oligometastatic anal squamous cell carcinoma: A case series and literature review. <i>Journal of Surgical Oncology</i> , <b>2019</b> , 119, 489-496	2.8	6
100	Biliary Stenting in Patients With Pancreatic Cancer: Results From a Population-Based Cohort Study. <i>Pancreas</i> , <b>2018</b> , 47, 80-86	2.6	6
99	Intratumoural expression of deoxycytidylate deaminase or ribonucleotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 1084-1088	8.7	5
98	Assessing the invariance of a culturally competent multi-lingual unmet needs survey for immigrant and Australian-born cancer patients: a Rasch analysis. <i>Quality of Life Research</i> , <b>2014</b> , 23, 2819-30	3.7	5
97	Phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) versus gemcitabine (Gem) alone for patients with resected pancreatic cancer (PC): Outcomes by geographic region.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4515-4515	2.2	5
96	Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GETO). <i>Annals of</i>	10.3	5
95	Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in Advanced Gastric Cancer. <i>Oncologist</i> , <b>2019</b> , 24, e1102-e1107	5.7	5
94	APACT: A phase 3 randomized, open-label, multicenter trial evaluating the use of adjuvant nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with surgically resected ductal pancreatic adenocarcinoma (PDA).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS4162-TPS4162	2.2	4
93	A multicenter, phase II trial of preoperative gemcitabine and nab-paclitaxel for resectable pancreas cancer: The AGITG GAP study.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4115-4115	2.2	4
92	A multicenter, phase II trial of preoperative gemcitabine and nab-paclitaxel for resectable pancreas cancer: The AGITG GAP study.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 387-387	2.2	4
91	Nomogram for predicting overall survival (OS) in patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) or Gem alone for metastatic pancreatic cancer (MPC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4109-4109	2.2	4
90	Circulating tumor DNA as a prognostic biomarker in early stage pancreatic cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e16206-e16206	2.2	4
89	Assessment of the Value of Tumor Variation Profiling Perceived by Patients With Cancer. <i>JAMA Network Open</i> , <b>2020</b> , 3, e204721	10.4	4
88	Oxaliplatin-induced haematological toxicity and splenomegaly in mice. <i>PLoS ONE</i> , <b>2020</b> , 15, e0238164	3.7	4
87	Corneal nerve changes following treatment with neurotoxic anticancer drugs. <i>Ocular Surface</i> , <b>2021</b> , 21, 221-237	6.5	4
86	Antitumour effects and mechanisms of action of the panHER inhibitor, dacomitinib, alone and in combination with the STAT3 inhibitor, S3I-201, in human sarcoma cell lines. <i>International Journal of Oncology</i> , <b>2018</b> , 52, 2143-2154	4.4	4

85	Performance status dynamics during treatment with -paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer. <i>Cancer Management and Research</i> , <b>2018</b> , 10, 1389-1396	3.6	3
84	Cancer survivorship outcomes in immigrants.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 6111-6111	2.2	3
83	Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4059-4059	2.2	3
82	Analysis of metabolic response (MR) by positron emission tomography (PET) compared with tumor response by computed tomography (CT) from MPACT, a phase III trial comparing nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone for patients (pts) with metastatic adenocarcinoma of the pancreas.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 254-254	2.2	3
81	TOPS: A randomised controlled trial of a multidisciplinary intervention for post-cancer fatigue.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 9571-9571	2.2	3
80	Initial survival outcomes for the AGITG GAP study [a phase II study of perioperative nab-paclitaxel and gemcitabine for resectable pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4105-4105	2.2	3
79	Evaluation of circulating VEGF based biomarkers in INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC) [a study by the Australasian Gastrointestinal Trials Group (AGITG).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 64-64	2.2	3
78	Neutrophil count and efficacy of chemoradiation in patients with locally advanced unresectable pancreatic carcinoma: An ancillary study of in the LAP 07 trial.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4120-4120	2.2	3
77	Patients' preferences for 3 months versus 6 months of adjuvant chemotherapy (ACT) for colon cancer in the SCOT trial: what survival benefits make longer chemotherapy worthwhile?. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3602-3602	2.2	3
76	The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy. <i>Acta Oncologica</i> , <b>2020</b> , 59, 20-27	3.2	3
75	Circulating tumour cells in pancreatic cancer: A systematic review and meta-analysis of clinicopathological implications. <i>Pancreatology</i> , <b>2021</b> , 21, 103-114	3.8	3
74	Systemic treatment in advanced biliary cancers: A multicenter Australian analysis and review. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2017</b> , 13, e291-e297	1.9	2
73	Impact of migrancy on cancer clinical trial participation: Factors associated with approach and consent in Australian-born versus migrant groups. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2020</b> , 16, 115-122	1.9	2
72	The role of chemotherapy in gastric cancer-related microangiopathic haemolytic anaemia. <i>Journal of Gastrointestinal Oncology</i> , <b>2017</b> , 8, E10-E15	2.8	2
71	Radiotherapy for anal squamous cell carcinoma: must the upper pelvic nodes and the inguinal nodes be treated?. <i>ANZ Journal of Surgery</i> , <b>2018</b> , 88, 870-875	1	2
70	Multimodal quantitative examination of nerve function in colorectal cancer patients prior to chemotherapy. <i>Muscle and Nerve</i> , <b>2018</b> , 57, 615-621	3.4	2
69	Modification of leucovorin dose within a simplified FOLFOX regimen improves tolerability without compromising efficacy. <i>Clinical Colorectal Cancer</i> , <b>2007</b> , 6, 578-82	3.8	2
68	Response of Carney's triad-related metastatic gastrointestinal stromal tumor to sunitinib. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2008</b> , 4, 170-174	1.9	2

67	Hypersensitivity reactions to oxaliplatin: Can patients be rechallenged?. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2006</b> , 2, 175-179	1.9	2
66	Predictors of resilience in women treated for breast cancer: A prospective study.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 9044-9044	2.2	2
65	CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4058-4058	2.2	2
64	INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced esophagogastric cancer (AOGC)A study by the Australasian Gastrointestinal Trials Group (AGITG).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS4157-TPS4157	2.2	2
63	Human equilibrative nucleoside transporter 1 (hENT1) in gemcitabine and FOLFOX (oxaliplatin, 5-fluorouracil, and leucovorin)-treated patients with metastatic pancreatic cancer: The randomized phase II PAN1 study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 228-228	2.2	2
62	Outcome of second-line treatment (2L Tx) following nab-paclitaxel (nab-P) + gemcitabine (G) or G alone for metastatic pancreatic cancer (MPC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 333-333	2.2	2
61	NUC-1031 in combination with cisplatin for first-line treatment of advanced biliary tract cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS4156-TPS4156	2.2	2
60	Corneal dendritic cells and the subbasal nerve plexus following neurotoxic treatment with oxaliplatin or paclitaxel. <i>Scientific Reports</i> , <b>2021</b> , 11, 22884	4.9	2
59	GOFURTGO trial (GFG): An AGITG multicenter phase II study of fixed dose rate gemcitabine-oxaliplatin (Gem-Ox) integrated with concomitant 5FU and 3-D conformal radiotherapy (5FU-3DRT) for the treatment of locally advanced pancreatic cancer (LAPC). <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 4616-4616	2.2	2
58	Clinical assessment of chemotherapy-induced peripheral neuropathy: a discrete choice experiment of patient preferences. <i>Supportive Care in Cancer</i> , <b>2021</b> , 29, 6379-6387	3.9	2
57	Effectively communicating comprehensive tumor genomic profiling results: Mitigating uncertainty for advanced cancer patients. <i>Patient Education and Counseling</i> , <b>2021</b> , 105, 452-452	3.1	2
56	Inflammatory Markers Have a Role in Renal Cell Carcinoma Prognosis. <i>European Urology Focus</i> , <b>2016</b> , 2, 341-342	5.1	2
55	Evaluation of Phase II Trial Design in Advanced Pancreatic Cancer. <i>Pancreas</i> , <b>2019</b> , 48, 1274-1284	2.6	2
54	Family communication about genomic sequencing: A qualitative study with cancer patients and relatives. <i>Patient Education and Counseling</i> , <b>2021</b> , 104, 944-952	3.1	2
53	Investigation of Relation of Radiation Therapy Quality With Toxicity and Survival in LAP07 Phase 3 Trial for Locally Advanced Pancreatic Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2021</b> , 110, 993-1002	4	2
52	Targeted therapy in soft tissue sarcoma-a novel direction in therapeutics. <i>Chinese Clinical Oncology</i> , <b>2013</b> , 2, 22	2.3	2
51	Self-reported health, lifestyle and social circumstances of Australian adult cancer survivors: A propensity score weighted cross-sectional study. <i>Cancer Epidemiology</i> , <b>2020</b> , 67, 101773	2.8	1
50	Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. <i>Expert Review of Anticancer Therapy</i> , <b>2017</b> , 17, 951-964	3.5	1

49	The successful management of two pregnancies with wild type metastatic gastrointestinal stromal tumors. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2009</b> , 5, 187-192	1.9	1
48	Disparities in quality-of-life outcomes in immigrant cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e16507-e16507	2.2	1
47	Correlation of KIT and PDGFRA mutational status with clinical benefit in patients (pts) with gastrointestinal stromal tumor (GIST) treated with sunitinib (SU) in a worldwide treatment-use (TU) trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 10549-10549	2.2	1
46	Genetic associations of fatigue and other symptom domains after breast cancer treatment: Results from a prospective cohort study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 9537-9537	2.2	1
45	Circulating biomarkers and outcomes in a single-arm phase II trial of first-line sunitinib alternating with everolimus for advanced renal cell carcinoma (aRCC): EVERSUN ANZUP trial 0901.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 428-428	2.2	1
44	Antiangiogenic agents (AAs) in metastatic oesophago-gastric cancer (mOGC): A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e15111-e15111	2.2	1
43	Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1): A randomized, multidisciplinary, multinational phase III trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS4140-TPS4140	2.2	1
42	nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone as adjuvant treatment for resected pancreatic cancer (PC) in a phase III trial (APACT).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS4153-TPS4153	2.2	1
41	Prognosis model for overall survival in locally advanced unresectable pancreatic carcinoma: An ancillary study of the LAP 07 trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 235-235	2.2	1
40	Tumor reduction in pancreatic versus metastatic sites in a randomized phase III study (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 382-382	2.2	1
39	Correlation of phase 2 trials (Ph2t) results with outcomes of phase 3 trials (Ph3t) of investigational agents (IA) in locally advanced and metastatic pancreas cancer (LAMPC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 227-227	2.2	1
38	Concordance between independent and investigator assessment of disease-free survival (DFS) in the APACT trial.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4618-4618	2.2	1
37	The synergistic inhibitory effect of combining therapies targeting EGFR and mitochondria in sarcomas. <i>Oncotarget</i> , <b>2020</b> , 11, 46-61	3.3	1
36	Psychological predictors of advanced cancer patients' preferences for return of results from comprehensive tumor genomic profiling. <i>American Journal of Medical Genetics, Part A</i> , <b>2021</b> ,	2.5	1
35	Barriers and enablers to the implementation of protocol-based imaging in pancreatic cancer: A qualitative study using the theoretical domains framework. <i>PLoS ONE</i> , <b>2020</b> , 15, e0243312	3.7	1
34	Analyses of updated overall survival (OS) and prognostic effect of neutrophil-to-lymphocyte ratio (NLR) and CA 19-9 from the phase III MPACT study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem for patients (pts) with metastatic pancreatic cancer (PC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4027-4027	2.2	1
33	Advanced cancer patient preferences for receiving molecular profiling results. <i>Psycho-Oncology</i> , <b>2020</b> , 29, 1533-1539	3.9	1
32	Determining the CA19-9 concentration that best predicts the presence of CT-occult unresectable features in patients with pancreatic cancer: A population-based analysis. <i>Pancreatology</i> , <b>2020</b> , 20, 1458-1464	3.8	1

31	Reply letter to comments on: Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis. <i>British Journal of Cancer</i> , <b>2020</b> , 123, 1466	8.7	1
30	Does the Microenvironment Hold the Hidden Key for Functional Precision Medicine in Pancreatic Cancer?. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
29	Australasian Gastro-Intestinal Trials Group (AGITG) MASTERPLAN: Randomized phase II study of modified neoadjuvant FOLFIRINOX alone or in combination with stereotactic radiotherapy (SBRT) for patients with high-risk and locally advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS4172-TPS4172	2.2	1
28	Value of whole-genome sequencing to Australian cancer patients and their first-degree relatives participating in a genomic sequencing study. <i>Journal of Genetic Counseling</i> , <b>2021</b> ,	2.5	1
27	Genetic associations of fatigue and other symptoms following breast cancer treatment: A prospective study. <i>Brain, Behavior, &amp; Immunity - Health</i> , <b>2021</b> , 10, 100189	5.1	1
26	AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer. <i>BMC Cancer</i> , <b>2021</b> , 21, 936	4.8	1
25	Evidence of slow and variable choice-stepping reaction time in cancer survivors with chemotherapy-induced peripheral neuropathy. <i>Gait and Posture</i> , <b>2021</b> , 89, 178-185	2.6	1
24	The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours.. <i>Targeted Oncology</i> , <b>2022</b> , 17, 95	5	1
23	The unmet needs of cancer survivors and their preferences for discussing them with oncologists and general practitioners (GPs).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 9602-9602	2.2	0
22	Medical oncologists' experience with returning molecular tumor profiling to patients.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 10521-10521	2.2	0
21	Development and consensus process for a clinical pathway for the assessment and management of chemotherapy-induced peripheral neuropathy.. <i>Supportive Care in Cancer</i> , <b>2022</b> , 1	3.9	0
20	Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use. <i>Quality of Life Research</i> ,	3.7	0
19	Response. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	
18	Reply to A. Giacalone et al. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4175-4176	2.2	
17	INTEGRATE IIb: A randomized phase III open label study of regorafenib + nivolumab versus standard chemotherapy in refractory advanced gastroesophageal cancer (AGOC).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, TPS366-TPS366	2.2	
16	Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. <i>Expert Review of Anticancer Therapy</i> , <b>2021</b> , 1-13	3.5	
15	The effect of exercise intensity on exercise-induced hypoalgesia in cancer survivors: A randomized crossover trial. <i>Physiological Reports</i> , <b>2021</b> , 9, e15047	2.6	
14	Return of results after somatic tumor mutation profiling in advanced cancer: Psychological impacts.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1541-1541	2.2	

13	Determining the impact of chemotherapy-induced peripheral neuropathy: A survey of cancer survivors.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e24080-e24080	2.2
12	Prognosis model for overall survival in locally advanced pancreatic cancer (LAPC): An ancillary study of the LAP 07 trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4024-4024	2.2
11	Reduction in primary pancreatic and metastatic tumor burden in the phase III MPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e15299-e15299	2.2
10	Systemic therapy in elderly patients with advanced biliary tract cancer: Sub-analysis of ABC-02 and 10 other prospective studies.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 382-382	2.2
9	ATTACHE: A phase III, multicenter, randomized comparison of chemotherapy given prior to and post surgical resection versus chemotherapy given post surgical resection for hepatic metastases from colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, TPS3643-TPS3643	2.2
8	Usefulness of medical oncologists' estimates of survival time in people with advanced cancer.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 9087-9087	2.2
7	PAN1: A randomized phase II study evaluating potential predictive biomarkers in the treatment of metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, TPS4137-TPS4137	2.2
6	Should culture affect practice? Prognostic discussions with immigrants.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 6556-6556	2.2
5	Significance of baseline quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4053-4053	2.2
4	EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (aRCC) (ANZUP trial 0901).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 438-438	2.2
3	Longitudinal patterns in fear of cancer progression in patients with rare, advanced cancers undergoing comprehensive tumour genomic profiling. <i>Psycho-Oncology</i> , <b>2021</b> , 30, 1920-1929	3.9
2	Radiation Therapy Deviations in Trial of Locally Advanced Prostate Cancer-Reply. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 316, 1409-1410	27.4
1	Gender representation in authorship in later-phase systemic clinical trials in biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 348-348	2.2